Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Capital Expenditures (2016 - 2026)

Akebia Therapeutics has reported Capital Expenditures over the past 9 years, most recently at $70000.0 for Q4 2025.

  • Quarterly Capital Expenditures rose 3400.0% to $70000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $291000.0 through Dec 2025, up 781.82% year-over-year, with the annual reading at $291000.0 for FY2025, 781.82% up from the prior year.
  • Capital Expenditures was $70000.0 for Q4 2025 at Akebia Therapeutics, down from $77000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $126000.0 in Q2 2025 and troughed at $2000.0 in Q3 2024.
  • The 4-year median for Capital Expenditures is $59000.0 (2021), against an average of $55222.2.
  • Year-over-year, Capital Expenditures surged 93.22% in 2022 and then skyrocketed 3750.0% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at $59000.0 in 2021, then surged by 93.22% to $114000.0 in 2022, then plummeted by 98.25% to $2000.0 in 2024, then surged by 3400.0% to $70000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Capital Expenditures are $70000.0 (Q4 2025), $77000.0 (Q3 2025), and $126000.0 (Q2 2025).